Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI + MEHD7945A versus FOLFIRI + cetuximab in second-line KRAS wild-type metastatic colorectal cancer
2011-005547-27Phase 2Terminated
- Sponsor
- Genentech
- Start
- Jul 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of duligotuzumab, cetuximab, irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC), metastatic colorectal adenocarcinoma (mCRC), colon adenocarcinoma and 1 more (2 arms), sponsored by Genentech. Primary endpoint: Progression-free survival. Started Jul 2012; status: terminated.
02
Drugs
duligotuzumabcetuximabirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on 2011-005547-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005547-27.